Moderna says its COVID-19 vaccine is nearly 95 percent effective
Two leading candidates have now reported preliminary data showing success in preventing illness
Updated
Editor’s note: This story was updated to include results of a fuller analysis released by Moderna on November 30.
On the heels of the preliminary success of one COVID-19 vaccine in the United States, another leading vaccine candidate is showing promise. Preliminary results indicate that Moderna’s coronavirus vaccine is nearly 95 percent effective in preventing sickness, including severe cases of the disease, the biotechnology company announced November 16.
“This is a pivotal moment in the development of our COVID-19 vaccine candidate,” Moderna CEO Stéphane Bancel said in a news release. The results are the “first clinical validation that our vaccine can prevent COVID-19 disease.”